Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Type

Guidance programme

Area of interest

Showing 11 to 12 of 12

TitleType
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All